Literature DB >> 20129625

Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2.

Elide Mantuano1, Silvia Romano, Liana Veneziano, Cinzia Gellera, Barbara Castellotti, Sara Caimi, Daniela Testa, Margherita Estienne, Giovanna Zorzi, Marianna Bugiani, Yusuf A Rajabally, Maria J Garcìa Barcina, Serena Servidei, Aurora Panico, Marina Frontali, Caterina Mariotti.   

Abstract

Episodic ataxia type 2 is a rare autosomal dominant disease characterized by recurrent attacks of vertigo and cerebellar ataxia. The disease was caused by mutations in the CACNA1A gene, on chromosome 19p. We perform a mutational screening in a group of 43 unrelated patients. Forty-two patients presented episodes of disequilibrium and ataxia, and one child was studied because of the occurrence of episodic torticollis. The genetic analysis showed 15 mutated patients (35%). In 13 cases we found novel CACNA1A gene mutations, including missense, protein truncating, and aberrant splicing mutations. Two truncating mutations lead to the uppermost premature stop so far reported, challenging recent hypotheses on dominant negative effect. In patients without CACNA1A mutations, molecular testing for CACNB4 gene mutations excluded this genetic subtype. Clinical features of mutated subjects mostly confirmed previous sign and symptoms associated with EA2, including paroxysmal torticollis and mental retardation. CACNA1A mutated patients have an earlier age at onset, interictal nystagmus, and abnormalities of ocular movements. A review of all CACNA1A mutations so far reported showed that they are mainly located downstream exon 18. Our data substantially increase the number of the described CACNA1A mutations, and propose clinical and molecular criteria for a more focused genetic screening. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20129625     DOI: 10.1016/j.jns.2010.01.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  27 in total

1.  Epilepsy and episodic ataxia type 2: family study and review of the literature.

Authors:  Lorenzo Verriello; Giada Pauletto; Annacarmen Nilo; Incoronata Lonigro; Elena Betto; Mariarosaria Valente; Francesco Curcio; Gian Luigi Gigli
Journal:  J Neurol       Date:  2021-05-13       Impact factor: 4.849

Review 2.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

Review 3.  Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.

Authors:  Sanjeev Rajakulendran; Diego Kaski; Michael G Hanna
Journal:  Nat Rev Neurol       Date:  2012-01-17       Impact factor: 42.937

4.  CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms.

Authors:  Lena Damaj; Alexis Lupien-Meilleur; Anne Lortie; Émilie Riou; Luis H Ospina; Louise Gagnon; Catherine Vanasse; Elsa Rossignol
Journal:  Eur J Hum Genet       Date:  2015-03-04       Impact factor: 4.246

5.  Ubiquitin Ligase RNF138 Promotes Episodic Ataxia Type 2-Associated Aberrant Degradation of Human Cav2.1 (P/Q-Type) Calcium Channels.

Authors:  Ssu-Ju Fu; Chung-Jiuan Jeng; Chia-Hao Ma; Yi-Jheng Peng; Chi-Ming Lee; Ya-Ching Fang; Yi-Ching Lee; Sung-Chun Tang; Meng-Chun Hu; Chih-Yung Tang
Journal:  J Neurosci       Date:  2017-02-06       Impact factor: 6.167

Review 6.  Update on diagnosis and differential diagnosis of vestibular migraine.

Authors:  Youjin Shen; Xiaokun Qi
Journal:  Neurol Sci       Date:  2022-01-11       Impact factor: 3.307

7.  Novel CACNA1A mutation(s) associated with slow saccade velocities.

Authors:  Stefan Kipfer; Simon Jung; Johannes R Lemke; Anna Kipfer-Kauer; Jeremy P Howell; Alain Kaelin-Lang; Thomas Nyffeler; Klemens Gutbrod; Angela Abicht; René M Müri
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

8.  Targeted exome analysis identifies the genetic basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes.

Authors:  Miao Sun; Amy Knight Johnson; Viswateja Nelakuditi; Lucia Guidugli; David Fischer; Kelly Arndt; Lan Ma; Erin Sandford; Vikram Shakkottai; Kym Boycott; Jodi Warman-Chardon; Zejuan Li; Daniela Del Gaudio; Margit Burmeister; Christopher M Gomez; Darrel J Waggoner; Soma Das
Journal:  Genet Med       Date:  2018-06-18       Impact factor: 8.822

9.  Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports.

Authors:  Seunghee Na; Taewon Kim
Journal:  Neurol Sci       Date:  2021-06-03       Impact factor: 3.307

Review 10.  Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.

Authors:  Wolfgang Nachbauer; Michael Nocker; Elfriede Karner; Iva Stankovic; Iris Unterberger; Andreas Eigentler; Rainer Schneider; Werner Poewe; Margarete Delazer; Sylvia Boesch
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.